ALLMedicine™ Hypophosphatemia Center

Sep 9th, 2021 - Refeeding hypophosphatemia (RH) in individuals with anorexia nervosa (AN) is a potentially fatal complication of nutrition restoration; yet, little is known about risk. This retrospective cohort study examined factors found in hospitalized youth w...

Sep 3rd, 2021 - Critical patients with Acute Kidney Injury (AKI) requiring renal replacement therapy are in most cases eligible only for continuous modalities where the electrolyte balance control is a critical issue. The standard solutions used for hemodiafiltra...

Aug 28th, 2021 - Autosomal dominant hypophosphatemic rickets (ADHR) is an extremely rare form of genetic rickets caused by mutations in the fibroblast growth factor 23 gene. ADHR is characterized by hypophosphatemia secondary to isolated renal phosphate wasting. O...

Aug 19th, 2021 - Enthesopathies are the determinant of a poor quality of life in adults with X-linked hypophosphatemia (XLH). To describe the prevalence of patients with enthesopathies and to identify the risk factors of having enthesopathies. Retrospective study ...

Aug 14th, 2021 - Hypophosphatemia may be a useful biomarker to identify thiamine deficiency in critically ill enterally-fed patients. The objective was to determine whether intravenous thiamine affects blood lactate, biochemical and clinical outcomes in this group...

Feb 19th, 2018 - To assess the safety of an investigational intravenous iron (ferric carboxymaltose [FCM]) or an equal dose of iron dextran and explore the mechanism of hypophosphatemia following administration of FCM or that of an equal dose of iron dextran when ...

Jun 22nd, 2021 - Camidanlumab tesirine (ADCT-301) was found to elicit an objective response rate (ORR) of 66.3% in patients with relapsed/refractory Hodgkin lymphoma, according to interim data from a phase 2 study (NCT04052997) presented during the 16th Internatio...

Jan 13th, 2021 - The histone deacetylase (HDAC) inhibitor entinostat failed to overcome resistance to endocrine therapy in hormone receptor–positive, HER2-negative, advanced breast cancer in a phase 3 trial. The study showed no difference in response, progression-...

Dec 20th, 2020 - Caron Jacobson, MD A manageable safety profile was observed for the combination of atezolizumab (Tecentriq) and the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel; Yescarta), in patients with refractory...

Dec 20th, 2020 - Tiragolumab in combination with atezolizumab (Tecentriq) demonstrated early clinical activity and was found to be well tolerated in patients with advanced solid tumors, including those with metastatic non–small cell lung cancer (NSCLC) who were PD...

Dec 5th, 2020 - %u25BA PHASE III Is Combination or Sequential Treatment for Metastatic Colorectal Cancer More Effective? Optimal treatment of advanced colorectal cancer is still very much a dynamic question. In order to determine whether combination tre...